NuvoAir, a digital healthcare company working in chronic disease management, raised $11M in a latest round of financing. The investment was led by Hikma Pharmaceuticals' venture capital arm, Hikma Ventures, and is an extension of the Series A round, previously announced in June 2021. Additional participation from a new strategic investor and existing investors brings the total Series A round to $25 million.

NuvoAir is a leading digital health company for chronic disease management and decentralized clinical trials. NuvoAir delivers a more continuous, relationship-based, coordinated and human-centric experience to individuals with complex conditions, with an initial focus on respiratory diseases. NuvoAir partners with health plans and risk-bearing providers with the goal to fully align incentives under a value-based care framework.